Introduction
c-erbB-2, located on chromosome 17, encodes a 185-kDa transmembrane tyrosine kinase receptor, which belongs to the growth factor receptor family. In carcinomas, cerbB-2 acts as an oncogene, mainly because high-level amplification of the gene induces protein overexpression (p185) in the cellular membrane [1] . Identifying these c-erbB-2 abnormalities in breast cancer is of interest, since trastuzumab (Herceptin; Roche Pharma, Neuilly sur Seine, France), a monoclonal antibody against the c-erbB-2 gene product, has proved effective in such patients. The c-erbB-2 protein has been found to be overexpressed in gastric carcinoma [2] , suggesting that anti-c-erbB-2 antibody therapy could be used. was a combination of trastuzumab and oxaliplatin: trastuzumab (Herceptin: 4 mg/kg for the first weekly injection, followed by 2 mg/kg for the next weekly injections) and oxaliplatin (Eloxatine, Sanofi-Aventis, Paris, France: 100 mg/m 2 per injection every other week). Complete remission was observed after 3 months of treatment. Peripheral neuropathy was observed, so oxaliplatin was stopped and trastuzumab was continued alone. The treatment with trastuzumab alone lasted for 18 months.
In July 2002, a CT scan revealed bilateral lung metastases, with three nodules, each less than 1 cm in diameter, in the upper right and left lobes and in the inferior right lobe. Pelvic examination showed a pelvic mass of 6 ¥ 5.5 ¥ 4 cm anchored to the sigmoid. A sigmoidectomy was performed and the peritoneal nodules were removed, but the patient refused lung surgery. 
Histopathology of the primary tumor
The primary gastric tumor measured 5 ¥ 3 cm and was staged pT3 according to the UICC classification. The pathologist diagnosed well-differentiated adenocarcinoma (intestinal type according to Lauren's classification), organized in tubular formations (Fig. 1) . Six lymph nodes were metastatic out of the eight resected during the lymph node dissection (stage pN1).
The histological analysis of the right ovary tumor (17 ¥ 15 ¥ 8 cm) confirmed that the metastasis came from the primary gastric tumor. No other pelvic metastasis was diagnosed in the left ovary, the uterus, or the omentum.
The pathological analysis of all pelvic and intestinal metastases revealed the presence of adenocarcinomatous cells, originating from the primary gastric tumor.
Immunohistochemistry
To assess c-erbB-2 expression, the primary gastric tumor was scored according to the criteria recommended by Dako for the Herceptest. Dako clone A 485 antibody was used. Interpretation revealed strong (3 +) membrane staining (Fig. 2) .
Discussion
In gastric cancer, overexpression of c-erB-2 protein, detected by immunohistochemistry, was first described in 1986 [2] . According to a recent study using fluorescence in situ hybridization (FISH), this overexpression is well correlated with gene amplification and both are detected in approximately 7% of gastric cancer cases [3] , without a clear relationship with histological subtypes. The mechanisms of p185 protein overexpression and of the high-level amplification of c-erbB-2 in gastric cancer are similar to those observed in breast cancer [1] .
Patients with a breast tumor showing Her-2 gene amplification and protein overexpression have an inferior prognosis, with shorter disease-free and overall survivals [1, 4] . The prognostic significance of Her-2/ neu overexpression was studied in gastric carcinoma. An especially low survival probability was reported for tumor-resected patients with an immunohistochemical c-erbB-2 score of 2 or 3 [5] ; their overall survival was 29 months vs 42 months for those with a tumor negative for c-erbB-2. In our study, the expression of the c-erbB-2 gene appeared as an independent biological risk factor, and a significant association between the expression of Her-2/neu and proteases involved in invasion and metastasis was observed. In gastric cancer, c-erbB-2 overexpression seems to be the second poorest prognostic variable after nodal status [6] , but its prognostic role is significant only in early-stage tumors [7] .
Little is known about the prognostic value of c-erbB-2 overexpression in metastatic gastric carcinoma. In metastatic breast cancer, trastuzumab significantly enhances the activity of first-line chemotherapy and enhances survival in women with Her-2-overexpressing breast cancer [8] . In the same way, gastric adenocarcinomas with strong membrane staining (3 +) are potential targets for this new treatment. The effectiveness of this c-erbB-2 targeting antibody in the inhibition of the growth of gastric cancer cell lines was recently reported [9] , but, to our knowledge, trastuzumab has not yet been studied systematically as an indication for c-erbB-2 protein overexpressing gastric cancer.
In the present patient, the tumor was a metastatic well-differentiated gastric adenocarcinoma, and showed strong (3 +) membrane staining on immunohistochemistry. The patient was efficiently treated with the combination of trastuzumab and oxaliplatin, which are effective drugs in the treatment of gastric cancer, and a complete response to peritoneal carcinomatosis was obtained. In a recent study, oxaliplatin in combination with 5-fluorouracil (5FU) and folinic acid led to a response rate of 45% for this tumor type [10] . Our patient developed grade 3 neurotoxicity, due to oxaliplatin, and trastuzumab was then given alone. Lung and peritoneal metastases developed despite the therapy. The disease was controlled again after reintroducing chemotherapy which had proved effective in the treatment of gastric cancer (oxaliplatin, then capecitabine) [10, 11] . The combination of trastuzumab and chemotherapy allowed for better disease control than immunotherapy alone, and an additive effect was suspected for the gastric tumor. In breast cancer, the combination of trastuzumab and chemotherapy is synergistic. Treatment with anthracycline, cyclophosphamide, paclitaxel, or vinorelbine, and trastuzumab is more efficient than monotherapy, with the objective response rate increasing from 26% to 50%, and an improved overall survival (25.1 vs 20.3 months; P = 0.046) [12, 13] . The median survival of patients with metastatic gastric cancer treated by chemotherapy alone is 9 months [14] . In contrast, our patient survived for 4 years with metastatic disease controlled for 2 years by immunochemotherapy. This extended survival, perhaps favored by unexpectedly weak activity of the tumor, suggests that it will be of high interest to further evaluate the combination of trastuzumab and chemotherapy in the treatment of gastric carcinoma with overexpression of the c-erbB-2 protein.
